BD Launches Innovative Central Venous Catheter System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Source: PRnewswire
Becton Dickinson and Co (BD) has seen its stock price decline by 3.02%, hitting a 52-week low amid mixed market conditions, with the Nasdaq-100 slightly up and the S&P 500 down.
The core catalyst for BD's recent developments is the launch of the CentroVena One™ Insertion System, the first all-in-one central venous catheter device designed to enhance patient safety and streamline procedures for clinicians. This product innovation is expected to significantly impact BD's market presence in the acute care sector, demonstrating the company's commitment to improving healthcare delivery.
The introduction of the CentroVena One™ not only expands BD's vascular access portfolio but also reflects its strategy to reduce complications associated with vascular access, potentially leading to improved clinical outcomes and economic benefits for healthcare providers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 155.540
Low
157.00
Averages
192.64
High
232.00
Current: 155.540
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surging Demand for GLP-1 Drugs Benefits Medical Device Companies
- Market Demand Surge: The demand for GLP-1 drugs is rapidly increasing, with companies like Eli Lilly and Novo Nordisk leading the market, although intensifying competition may lead to declining market share and pricing power.
- Becton, Dickinson Expansion Investment: Becton, Dickinson announced a $110 million investment to expand production capacity for injectable drugs to meet the soaring demand for GLP-1 medications, which is expected to enhance its competitiveness in the medical device market.
- Abbott Laboratories Growth Potential: Despite the rise of GLP-1 drugs, demand for Abbott's continuous glucose monitoring device, FreeStyle Libre, remains strong, and the combined use with GLP-1 medications may drive higher adoption rates for CGM devices.
- Stable Dividend Returns: Both Becton, Dickinson and Abbott Laboratories are Dividend Kings, having raised dividends for 54 consecutive years, demonstrating their stable revenue and profitability, which attracts long-term investors.
See More
Dividend Kings: Steady Growth Investment Choices
- Strong Dividend Growth: Johnson & Johnson has raised its dividend for 64 consecutive years, with a market cap of $624 billion and only 46% of its estimated 2026 earnings allocated for dividends, indicating robust financial health and growth potential.
- Global Beverage Giant: Coca-Cola has also increased its dividend for 64 years, maintaining a stable market cap, with dividends projected to consume 65% of its 2026 earnings, while analysts expect high single-digit earnings growth, ensuring long-term investment value.
- Innovator in Healthcare: Abbott Laboratories has a 54-year streak of dividend increases, focusing on diagnostics, diabetes, and cardiovascular care, with dividends accounting for just 46% of estimated 2026 earnings, and analysts forecasting around 10% annual growth, providing a solid foundation for future development.
- Leader in Household Goods: Procter & Gamble boasts a remarkable 70-year dividend growth record, and despite facing low growth pressures, its dividends represent 63% of estimated 2026 earnings, showcasing its strong competitive position and ability to sustain dividend growth.
See More
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
BD's CentroVena One™ Receives Vizient Innovative Technology Contract
- Innovative Technology Recognition: BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient, indicating its potential to simplify central line insertion and enhance patient safety, which is expected to drive significant improvements in healthcare delivery.
- Workflow Simplification Advantage: By integrating the guidewire, needle, syringe, and catheter into a single system, the CentroVena One™ reduces procedural steps by 30% and maximum procedure time by 50%, thereby lowering operational complexity and enhancing clinical efficiency.
- Safety-Focused Design Features: The design of CentroVena One™ incorporates safety elements aimed at reducing contamination risks and preventing complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure, further enhancing safety for both patients and clinicians.
- Market Impact: The Vizient contract encompasses over $156 billion in annual purchasing volume, allowing BD to enhance healthcare outcomes, lower costs, and expand access to healthcare through close collaboration with clients, thereby strengthening its competitive position in the medical technology market.
See More
Five Blue Chip Dividend Stocks Worth Holding Forever
- AbbVie's Stability: AbbVie (ABBV), a biopharmaceutical giant, has increased its dividends for 50 consecutive years since becoming independent in 2013, with 12 products exceeding $1 billion in sales by 2025, showcasing its strong market adaptability and long-term growth potential.
- McDonald's Expansion: McDonald's (MCD) operates over 45,000 restaurants globally and is expected to raise its dividend again this year, with analysts projecting high-single-digit earnings growth in the coming years, further solidifying its status as a premium dividend stock.
- Johnson & Johnson's Financial Health: Johnson & Johnson (JNJ) is renowned for its 64 consecutive years of dividend increases and boasts an AAA credit rating, with expected annual earnings growth averaging 8% to 9% over the next few years, demonstrating its robustness and reliability in the healthcare sector.
- Walmart's E-commerce Transformation: Walmart (WMT) has consistently increased its dividend for 53 years, and despite e-commerce competition, its earnings are projected to grow by an average of 9% over the next three to five years, providing strong support for continued dividend growth.
See More
Top Dividend Stocks in Healthcare and Consumer Sectors
- Dividend Growth Leader: AbbVie, a Dividend King since its independence in 2013, has raised its dividend for 50 consecutive years and boasts 12 products exceeding $1 billion in sales by 2025, showcasing its strong competitive position in the biopharmaceutical sector.
- Fast-Food Industry Giant: McDonald's operates over 45,000 locations globally and is expected to continue its dividend growth, with the dividend projected to be only 57% of estimated earnings in 2026, reflecting its robust profitability and ongoing market expansion potential.
- Healthcare Sector Leader: Johnson & Johnson is renowned for its 64 consecutive years of dividend increases, with analysts forecasting annual earnings growth of 8% to 9% over the coming years, demonstrating its resilience in pharmaceuticals and medical devices.
- Retail Giant's Resilience: Walmart has maintained and increased its dividend for 53 years, with expected average earnings growth of 9% over the next three to five years, and its dividend is only 34% of 2026 earnings estimates, indicating its adaptability and market leadership amid e-commerce competition.
See More
Surging Demand for GLP-1 Drugs Benefits Medical Device Companies
- Market Demand Surge: The demand for GLP-1 drugs is rapidly increasing, with companies like Eli Lilly and Novo Nordisk leading the market, although intensifying competition may lead to declining market share and pricing power.
- Becton, Dickinson Expansion Investment: Becton, Dickinson announced a $110 million investment to expand production capacity for injectable drugs to meet the soaring demand for GLP-1 medications, which is expected to enhance its competitiveness in the medical device market.
- Abbott Laboratories Growth Potential: Despite the rise of GLP-1 drugs, demand for Abbott's continuous glucose monitoring device, FreeStyle Libre, remains strong, and the combined use with GLP-1 medications may drive higher adoption rates for CGM devices.
- Stable Dividend Returns: Both Becton, Dickinson and Abbott Laboratories are Dividend Kings, having raised dividends for 54 consecutive years, demonstrating their stable revenue and profitability, which attracts long-term investors.
See More
Dividend Kings: Steady Growth Investment Choices
- Strong Dividend Growth: Johnson & Johnson has raised its dividend for 64 consecutive years, with a market cap of $624 billion and only 46% of its estimated 2026 earnings allocated for dividends, indicating robust financial health and growth potential.
- Global Beverage Giant: Coca-Cola has also increased its dividend for 64 years, maintaining a stable market cap, with dividends projected to consume 65% of its 2026 earnings, while analysts expect high single-digit earnings growth, ensuring long-term investment value.
- Innovator in Healthcare: Abbott Laboratories has a 54-year streak of dividend increases, focusing on diagnostics, diabetes, and cardiovascular care, with dividends accounting for just 46% of estimated 2026 earnings, and analysts forecasting around 10% annual growth, providing a solid foundation for future development.
- Leader in Household Goods: Procter & Gamble boasts a remarkable 70-year dividend growth record, and despite facing low growth pressures, its dividends represent 63% of estimated 2026 earnings, showcasing its strong competitive position and ability to sustain dividend growth.
See More
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
BD's CentroVena One™ Receives Vizient Innovative Technology Contract
- Innovative Technology Recognition: BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient, indicating its potential to simplify central line insertion and enhance patient safety, which is expected to drive significant improvements in healthcare delivery.
- Workflow Simplification Advantage: By integrating the guidewire, needle, syringe, and catheter into a single system, the CentroVena One™ reduces procedural steps by 30% and maximum procedure time by 50%, thereby lowering operational complexity and enhancing clinical efficiency.
- Safety-Focused Design Features: The design of CentroVena One™ incorporates safety elements aimed at reducing contamination risks and preventing complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure, further enhancing safety for both patients and clinicians.
- Market Impact: The Vizient contract encompasses over $156 billion in annual purchasing volume, allowing BD to enhance healthcare outcomes, lower costs, and expand access to healthcare through close collaboration with clients, thereby strengthening its competitive position in the medical technology market.
See More
Five Blue Chip Dividend Stocks Worth Holding Forever
- AbbVie's Stability: AbbVie (ABBV), a biopharmaceutical giant, has increased its dividends for 50 consecutive years since becoming independent in 2013, with 12 products exceeding $1 billion in sales by 2025, showcasing its strong market adaptability and long-term growth potential.
- McDonald's Expansion: McDonald's (MCD) operates over 45,000 restaurants globally and is expected to raise its dividend again this year, with analysts projecting high-single-digit earnings growth in the coming years, further solidifying its status as a premium dividend stock.
- Johnson & Johnson's Financial Health: Johnson & Johnson (JNJ) is renowned for its 64 consecutive years of dividend increases and boasts an AAA credit rating, with expected annual earnings growth averaging 8% to 9% over the next few years, demonstrating its robustness and reliability in the healthcare sector.
- Walmart's E-commerce Transformation: Walmart (WMT) has consistently increased its dividend for 53 years, and despite e-commerce competition, its earnings are projected to grow by an average of 9% over the next three to five years, providing strong support for continued dividend growth.
See More
Top Dividend Stocks in Healthcare and Consumer Sectors
- Dividend Growth Leader: AbbVie, a Dividend King since its independence in 2013, has raised its dividend for 50 consecutive years and boasts 12 products exceeding $1 billion in sales by 2025, showcasing its strong competitive position in the biopharmaceutical sector.
- Fast-Food Industry Giant: McDonald's operates over 45,000 locations globally and is expected to continue its dividend growth, with the dividend projected to be only 57% of estimated earnings in 2026, reflecting its robust profitability and ongoing market expansion potential.
- Healthcare Sector Leader: Johnson & Johnson is renowned for its 64 consecutive years of dividend increases, with analysts forecasting annual earnings growth of 8% to 9% over the coming years, demonstrating its resilience in pharmaceuticals and medical devices.
- Retail Giant's Resilience: Walmart has maintained and increased its dividend for 53 years, with expected average earnings growth of 9% over the next three to five years, and its dividend is only 34% of 2026 earnings estimates, indicating its adaptability and market leadership amid e-commerce competition.
See More
